Why the study?
Does aspirin pretreatment improve the anti-thrombotic and desaggregating efficacy of the GP-IIb/IIIa antagonist SR121566 in preclinical models?
Population
Rabbit model of carotid artery thrombosis (electrical stimulation) and human platelets in vitro
Comparison
Aspirin pretreatment followed by SR121566 vs SR121566 alone or control platelet-rich plasma
Design
Preclinical
Authors
Loading...
Does not support clinical use; leaves open whether aspirin augments GP-IIb/IIIa inhibitors in human thrombosis.
Does aspirin pretreatment improve the anti-thrombotic and desaggregating efficacy of the GP-IIb/IIIa antagonist SR121566 in preclinical models?
Aspirin pretreatment enhances the thrombolytic and desaggregating activity of GP-IIb/IIIa inhibitors by inhibiting the release of platelet granule contents, particularly thrombospondin.
Augusto Savi (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: